Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.

Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, Cauda R, Anzidei G, Cusato M, Regazzi M, Floridia M, Tamburrini E.

J Antimicrob Chemother. 2010 Sep;65(9):2050-2. doi: 10.1093/jac/dkq264. Epub 2010 Jul 14. No abstract available.

PMID:
20630894
2.

Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.

Wirden M, Marcelin AG, Tubiana R, Valantin MA, Ghosn J, Duvivier C, Dominguez S, Paris L, Agher R, Peytavin G, Katlama C, Calvez V.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):876-8. No abstract available.

PMID:
15213573
3.

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.

PMID:
12792350
4.

Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.

Lapadula G, Costarelli S, Quiros-Roldan E, Calabresi A, Izzo I, Carosi G, Torti C.

Clin Infect Dis. 2008 Apr 1;46(7):1127-9. doi: 10.1086/529394. No abstract available.

PMID:
18444839
5.

No residual activity of raltegravir after development of 148 complex mutations in vivo.

Khanlou H, Sayana S, Acosta E.

J Int Assoc Physicians AIDS Care (Chic). 2008 Nov-Dec;7(6):281-2. doi: 10.1177/1545109708327489. No abstract available.

PMID:
19164138
6.

Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.

Gutiérrez S, Guillemi S, Jahnke N, Montessori V, Harrigan PR, Montaner JS.

Clin Infect Dis. 2008 Feb 1;46(3):e28-30. doi: 10.1086/525857.

PMID:
18181733
7.

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.

Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M.

J Antimicrob Chemother. 2005 Dec;56(6):1087-93. Epub 2005 Nov 3.

PMID:
16269552
8.

Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.

J Antimicrob Chemother. 2009 Dec;64(6):1260-4. doi: 10.1093/jac/dkp348. Epub 2009 Sep 22.

PMID:
19776037
9.

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F.

Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749.

10.

Raltegravir: is a 400 mg once-daily dose enough?

Lanzafame M, Hill A, Lattuada E, Calcagno A, Bonora S.

J Antimicrob Chemother. 2010 Mar;65(3):595-7. doi: 10.1093/jac/dkp488. Epub 2010 Jan 12. No abstract available.

PMID:
20071368
11.

Initial results reported on raltegravir once-daily dosing.

[No authors listed]

AIDS Patient Care STDS. 2011 Feb;25(2):123. No abstract available.

PMID:
21370546
12.

Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.

Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.

J Med Virol. 2007 Feb;79(2):105-10.

PMID:
17177308
13.

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.

Manosuthi W, Lueangniyomkul A, Mankatitham W, Chimsuntorn S, Tantanathip P, Thongyen S, Suntisuklappon B, Nilkamhang S, Sungkanuparph S.

J Infect. 2011 May;62(5):406-9. doi: 10.1016/j.jinf.2011.02.012. Epub 2011 Mar 5. No abstract available.

PMID:
21382413
14.

Anti-HIV agents. Merck integrase inhibitor.

[No authors listed]

TreatmentUpdate. 2006 Aug-Sep;18(4):3-4. No abstract available.

PMID:
17205652
15.
16.

Should tenofovir ever be used in association with didanosine?

Diaz RS.

Braz J Infect Dis. 2005 Dec;9(6):452-3. Epub 2006 Jan 9. No abstract available.

17.

Advantages of low-cost generic tenofovir instead of D4T for first-line antiretroviral therapy in Burma: a 2-year experience.

Moore S, Myint MM, Galau NH.

AIDS. 2010 Jun 19;24(10):1606-7. doi: 10.1097/QAD.0b013e328338e47a. No abstract available.

PMID:
20539097
18.

Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.

TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.

AIDS. 2009 Apr 27;23(7):825-33. doi: 10.1097/QAD.0b013e32832949d5.

PMID:
19307941
19.
20.

Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

Parienti JJ.

J Antimicrob Chemother. 2009 May;63(5):1080; author reply 1080-1. doi: 10.1093/jac/dkn556. Epub 2009 Jan 21. No abstract available.

PMID:
19158108

Supplemental Content

Support Center